Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies

Current Cancer Drug Targets

Volumn 11, Issue 3, 2011, Pages 338-346

  Kona, F R ^a   Buac, D ^a   Burger, A M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer activity; Clinical trials; Copper; Disulfiram; Proteasome; Ubiquitin E3 ligases; Zinc; Zinc ejection

Indexed keywords

ANFD 24; ANTINEOPLASTIC AGENT; AZOFORMAMIDE; BORTEZOMIB; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIMETHYLHYDRAZINE; DISULFIRAM; DISULFIRAM DERIVATIVE; DPT 001; GLUCONATE ZINC; GLYCOPROTEIN P; IFOSFAMIDE; LACTACYSTIN; MDM2 INHIBITOR; MI 219; MI 319; MLN 4924; NSC 667089; NUTLIN 3; PROTEASOME; PROTEIN INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; TROFOSFAMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INHIBITION; CANCER REGRESSION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; CHRONIC LYMPHATIC LEUKEMIA; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; EYE MELANOMA; HUMAN; IC 50; LEUKEMIA CELL LINE; LEUKEMIA L 1210; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; MELANOMA CELL; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; OVARY CARCINOMA; PROSTATE CANCER; RECURRENT CANCER; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISULFIRAM; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 79951702170     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794519798     Document Type: Article

References (42)

1. Soghoian, S.; Wiener, S. W.; Díaz-Alcalá, J. E. Toxicity, disulfiram. Emedicine, Medscape.com. 2008 Aug. Available from: http://emedicinemedscape.com/article/814525-overview. [cited 2009 Jul 6].
2. Sauna, Z. E.; Shukla, S.; Ambudkar, S. V. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol. BioSyst. 2005, 124-134.
3. Schirmer, H. K.; Scott, W. W. Disulfiram and tumor inhibition. Trans. Am. Assoc. Genitourin. Surg. 1966, 58, 63-66.
4. Wattenberg, L. W. Inhibition of dimethylhydrazine-induced neoplasia of the large intestine by disulfiram. J. Natl. Cancer Inst. 1975, 54, 1005-1006.
5. Borchert, P.; Wattenberg, L. W. Inhibition of macromolecular binding of benzo(a)pyrene and inhibition of neoplasia by disulfiram in the mouse forestomach. J. Natl. Cancer Inst. 1976, 57, 173-179.
6. Sladek, N. E.; Landkamer, G. J. Restoration of sensitivity to ox-azaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res. 1985, 45, 1549-1555.
7. Valeriote, F.; Grates, H. E. Potentiation of nitrogen mustard cytotoxicity by disulfiram, diethyldithiocarbamic acid, and diethylamine in mice. Cancer Res. 1989, 49, 6658-6661.
8. Bodenner, D. L.; Dedon, P. C.; Keng, P. C.; Katz, J. C.; Borch, R. F. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithio-carbamate. Cancer Res. 1986, 46, 2751-2755.
9. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
10. Qazi, R.; Chang, A. Y.; Borch, R. F.; Montine, T.; Dedon, P.; Loughner, J.; Bennett, J. M. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J. Natl. Cancer Inst. 1988, 80, 1486-1488.
11. Verma, S.; Stewart, D. J.; Maroun, J. A.; Nair, R. C. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am. J. Clin. Oncol. 1990, 13, 119-124.
12. Loo, T. W.; Clarke, D. M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl. Cancer Inst. 2000, 92, 898-902.
13. Liu, G. Y.; Frank, N.; Bartsch, H.; Lin, J. K. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins. Mol. Carcinog. 1998, 22, 235-246.
14. Lin, J.; Haffner, M. C.; Zhang, Y.; Kachhap, S.; Liu, J.; Yegnasubramanian, S.; Nelson, W. G.; Carducci, M. A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 2010, Epub ahead of print.
15. Shian, S. G.; Kao, Y. R.; Wu, F. Y.; Wu, C. W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol. Pharmacol. 2003, 64, 1076-1084.
16. Weismann, K. Chelating drugs and zinc. Dan. Med. Bull. 1986 33, 208-211.
17. Lövborg, H.; Oberg, F.; Rickardson, L.; Gullbo, J.; Nygren P.; Larsson, R. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the anti-alcoholism drug disulfiram. Int. J. Cancer 2006, 118, 1577-1580.
18. Wickström, M.; Danielsson, K.; Rickardson, L.; Gullbo, J.; Nygren, P.; Isaksson, A.; Larsson, R.; Lövborg, H. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem. Pharmacol. 2007, 73, 25-33.
19. Rickardson, L.; Wickström, M.; Larsson, R.; Lövborg, H. Image-based screening for the identification of novel proteasome inhibitors. J. Biomol. Screen. 2007, 12, 203-210.
20. Chen, D.; Cui, Q. C.; Yang, H.; Dou, Q. P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66, 10425-10433.
21. Li, L.; Yang, H.; Chen, D.; Cui, C.; Dou, Q. P. Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. Toxicol. Appl. Pharmacol. 2008, 229, 206-214.
22. Yu, Z.; Wang, F.; Milacic, V.; Li, X.; Cui, Q. C.; Zhang, B.; Yan, B.; Dou, Q. P. Evaluation of copper-dependent proteasome-inhibitory and apoptosis-inducing activities of novel pyrrolidine dithiocarbamate analogues. Int. J. Mol. Med. 2007, 20, 919-925.
23. Suzuki, Y.; Fujii, S.; Tominaga, T.; Yoshimoto, T.; Yoshimura, T.; Kamada, H. The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines. Biochim. Biophys. Acta 1997, 1335, 242-245.
24. Brar, S. S.; Grigg, C.; Wilson, K. S.; Holder Jr, W. D.; Dreau, D.; Austin, C.; Foster, M.; Ghio, A. J.; Whorton, A. R.; Stowell, G.W.; Whittall, L. B.; Whittle, R. R.; White, D. P.; Kennedy, T. P. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol. Cancer Ther. 2004, 3, 1049-1060.
25. Burger, A. M.; Seth, A. K. The ubiquitin mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer 2004, 40, 2217-2229.
26. Burger, A. M.; Seth, A. K. Ubiquitin Ligases and Cancer. In: Modulation of Protein Stability in Cancer Therapy; Sakamoto, K.; Rubin, E. H., Eds.; Springer: New York, NY, 2009, pp. 1-18.
27. Kosarev, P.; Mayer, K. F. X.; Hardtke, C. S. Evaluation and classification of RING-finger domains encoded by the Arabidopsis genome. Genome Biol. 2002, 3, 1-12.
28. Deshaies, R. J.; Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78, 399-434.
29. Nalepa, G.; Rolfe, M.; Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5, 596-613.
30. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science 2004, 303, 844-8.
31. Mohammad, R. M.; Wu, J.; Azmi, A. S.; Aboukameel, A.; Sosin, A.; Wu, S.; Yang, D.; Wang, S.; Al-Katib, A-M. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol. Cancer 2009, 8, 115.
32. Soucy, T. A.; Smith, P. G.; Milhollen, M. A.; Berger, A. J.; Gavin, J. M.; Adhikari, S.; Brownell, J. E.; Burke, K. E.; Cardin, D. P.; Critchley, S.; Cullis, C. A.; Doucette, A.; Garnsey, J. J.; Gaulin, J. L.; Gershman, R. E.; Lublinsky, A. R.; McDonald, A.; Mizutani, H.; Narayanan, U.; Olhava, E. J.; Peluso, S.; Rezaei, M.; Sintchak, M. D.; Talreja, T.; Thomas, M. P.; Traore, T.; Vyskocil, S.; Weatherhead, G. S.; Yu, J.; Zhang, J.; Dick, L. R.; Claiborne, C. F.; Rolfe, M.; Bolen, J. B.; Langston, S. P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458, 732-736.
33. Rice, W. G.; Schaeffer, C. A.; Harten B.; Villinger, F.; South, T. L.; Summers, M. F.; Henderson, L. E.; Bess Jr, J. W.; Arthur, L. O.; McDougal, J. S.; Orloff, S. L.; Mendeleyev, J.; Kun E. Inhibition of HIV infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 1993, 361, 473-475.
34. Rice, W. G.; Turpin, J. A.; Huang, M.; Clanton, D.; Buckheit Jr, R. W.; Covell, D. G.; Wallqvist, A.; McDonnell, N. B.; DeGuzman, R. N.; Summers, M. F.; Zalkow, L.; Bader, J. P.; Haugwitz, R. D.; Sausville, E. A. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat. Med. 1997, 3, 341-345.
35. Nash, T.; Rice, W. G. Efficacies of Zinc-Finger-Active Drugs against Giardia lamblia. Antimicrob. Agents Chemother. 1998, 42, 1488-1492.
36. Beerheide, W.; Bernard, H. U.; Tan, Y. J.; Ganesan, A.; Rice, W. G.; Ting, A. E. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 onco-protein. J. Natl. Cancer Inst. 1999, 91, 1211-1220.
37. Burger, A. M.; Amemiya, Y.; Kitching, R.; Seth, A. K. Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 2006, 8, 689-695.
38. Burger, A. M.; Gao, Y.; Amemiya, Y.; Kahn, H. J.; Kitching, R.; Yang, Y.; Sun, P.; Narod, S. A.; Hanna, W. M.; Seth, A. K. A novel breast cancer associated RING-type ubiquitin ligase correlates with outcome in invasive breast cancer. Cancer Res. 2005, 65, 10401-10412.
39. Rice, W. G.; Baker, D. C.; Schaeffer, C. A.; Graham, L.; Bu, M.; Terpening, S.; Clanton, D.; Schultz, R.; Bader, J. P.; Buckheit Jr., R. W.; Field, L.; Singh, P. K.; Turpin, J. A. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. 1997, 419-426.
40. Brahemi, G.; Kona, F. R.; Fiasella, A.; Buac, D.; Soukupová, J.; Brancale, A.; Burger, A. M.; Westwell, A. D. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. J. Med. Chem. 2010, 53, 2757-2765.
41. Burger, A. M. Targeting leukemic stem cells. In: Stem Cells and Cancer; Bagley, R. G.; Teicher, B. A., Eds., Humana Press: New York, NY, 2009, pp. 263-273.
42. Ginestier, C.; Hur, M. H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C. G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M. S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1, 555-567.